{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T20:45:03Z","timestamp":1783975503797,"version":"3.55.0"},"reference-count":111,"publisher":"Becaris Publishing Limited","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:p>\n            <jats:bold>Aim:<\/jats:bold>\n            Alagille syndrome (ALGS) is a rare, cholestatic multiorgan disease associated with bile duct paucity, leading to cholestasis. Clinical symptoms of cholestasis include debilitating pruritus, xanthomas, fat-soluble vitamin deficiencies, growth failure, renal disease and impaired health-related quality of life (HRQoL). The main objective was to review the current literature on the epidemiological, clinical, psychosocial and economic burden of ALGS in view of the development of ileal bile acid transporter (IBAT) inhibitors.\n            <jats:bold>Methods:<\/jats:bold>\n            Electronic literature databases were searched in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses checklist.\n            <jats:bold>Results:<\/jats:bold>\n            330 publications were screened, 119 were relevant: 11 randomized controlled trials (RCTs), 21 non-RCTs, 10 HRQoL studies, two studies assessing cost\/resource use and 77 epidemiological studies across several databases through 31 July 2024. Studies confirm that patients with ALGS experience cardiac anomalies, impaired growth, renal disease, poor HRQoL, fat-soluble vitamin deficiencies and debilitating pruritus; until the approval of IBAT inhibitors for the treatment of cholestatic pruritus in patients with ALGS, supportive management was the standard of care.\n            <jats:bold>Conclusion:<\/jats:bold>\n            This review confirms the substantial clinical, economic and HRQoL burden associated with ALGS and consolidates current treatment evidence. Data from recent trials in ALGS demonstrate the potential impact of IBAT inhibitors to transform lives by improving cholestatic pruritus symptoms, HRQoL and native liver survival.\n          <\/jats:p>","DOI":"10.57264\/cer-2024-0188","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T14:16:14Z","timestamp":1737987374000},"source":"Crossref","is-referenced-by-count":6,"title":["The burden of Alagille syndrome: uncovering the potential of emerging therapeutics \u2013 a comprehensive systematic literature review"],"prefix":"10.57264","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5742-8273","authenticated-orcid":false,"given":"Philip","family":"Bufler","sequence":"first","affiliation":[{"name":"Department of Pediatric Gastroenterology, Nephrology &amp; Metabolic Diseases, Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, Germany"},{"name":"German Center for Child &amp; Adolescent Health (DZKJ), partner site Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3405-2103","authenticated-orcid":false,"given":"Robin","family":"Howard","sequence":"additional","affiliation":[{"name":"Mirum Pharmaceuticals, Inc., Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8850-2266","authenticated-orcid":false,"given":"Lucia","family":"Quadrado","sequence":"additional","affiliation":[{"name":"Mirum Pharmaceuticals, Inc., Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6048-4074","authenticated-orcid":false,"given":"Guy","family":"Lacey","sequence":"additional","affiliation":[{"name":"Mirum Pharmaceuticals, Inc., Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0315-3383","authenticated-orcid":false,"given":"Jolan","family":"Terner-Rosenthal","sequence":"additional","affiliation":[{"name":"Mirum Pharmaceuticals, Inc., Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5607-818X","authenticated-orcid":false,"given":"Andrea","family":"Goldstein","sequence":"additional","affiliation":[{"name":"Mirum Pharmaceuticals, Inc., Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4226-5435","authenticated-orcid":false,"given":"Pamela","family":"Vig","sequence":"additional","affiliation":[{"name":"Mirum Pharmaceuticals, Inc., Foster City, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9776-4354","authenticated-orcid":false,"given":"Deirdre","family":"Kelly","sequence":"additional","affiliation":[{"name":"Guy's &amp; St Thomas' NHS Foundation Trust, London, UK"},{"name":"Evelina London Women's &amp; Children's Clinical Group, Evelina London Children's Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"36897","reference":[{"issue":"2","key":"e_1_3_7_2_2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/MPG.0000000000001958","article-title":"Systematic review: the epidemiology, natural history, and burden of Alagille syndrome","volume":"67","author":"Kamath BM","year":"2018","unstructured":"Kamath BM, Baker A, Houwen R, Todorova L, Kerkar N. Systematic review: the epidemiology, natural history, and burden of Alagille syndrome. J. Pediatr. Gastroenterol. Nutr. 67(2), 148\u2013156 (2018).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"e_1_3_7_3_2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/TACG.S86420","article-title":"Alagille syndrome: clinical perspectives","volume":"9","author":"Saleh M","year":"2016","unstructured":"Saleh M, Kamath BM, Chitayat D. Alagille syndrome: clinical perspectives. Appl Clin Genet. 9, 75\u201382 (2016).","journal-title":"Appl Clin Genet."},{"issue":"3","key":"e_1_3_7_4_2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/ejhg.2011.181","article-title":"Alagille syndrome: pathogenesis, diagnosis and management","volume":"20","author":"Turnpenny PD","year":"2012","unstructured":"Turnpenny PD, Ellard S. Alagille syndrome: pathogenesis, diagnosis and management. Eur. J. Hum. Genet. 20(3), 251\u2013257 (2012).","journal-title":"Eur. J. Hum. Genet."},{"issue":"3","key":"e_1_3_7_5_2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/ng0797-243","article-title":"Alagille syndrome is caused by mutations in human JAGGED1, which encodes a ligand for NOTCH1","volume":"16","author":"Li L","year":"1997","unstructured":"Li L, Krantz ID, Deng Y Alagille syndrome is caused by mutations in human JAGGED1, which encodes a ligand for NOTCH1. Nat. Genet. 16(3), 243\u2013251 (1997).","journal-title":"Nat. Genet."},{"issue":"1","key":"e_1_3_7_6_2","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1086\/505332","article-title":"NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway","volume":"79","author":"McDaniell R","year":"2006","unstructured":"McDaniell R, Warthen DM, Sanchez-Lara PA NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. Am. J. Hum. Genet. 79(1), 169\u2013173 (2006).","journal-title":"Am. J. Hum. Genet."},{"issue":"3","key":"e_1_3_7_7_2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ng0797-235","article-title":"Mutations in the human JAGGED1 gene are responsible for Alagille syndrome","volume":"16","author":"Oda T","year":"1997","unstructured":"Oda T, Elkahloun AG, Pike BL Mutations in the human JAGGED1 gene are responsible for Alagille syndrome. Nat. Genet. 16(3), 235\u2013242 (1997).","journal-title":"Nat. Genet."},{"issue":"3","key":"e_1_3_7_8_2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s40139-017-0144-8","article-title":"Alagille syndrome: genetics and functional models","volume":"5","author":"Gilbert MA","year":"2017","unstructured":"Gilbert MA, Spinner NB. Alagille syndrome: genetics and functional models. Curr Pathobiol Rep. 5(3), 233\u2013241 (2017).","journal-title":"Curr Pathobiol Rep."},{"issue":"8","key":"e_1_3_7_9_2","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/lt.23437","article-title":"Outcomes of liver transplantation for patients with Alagille syndrome: the studies of pediatric liver transplantation experience","volume":"18","author":"Kamath BM","year":"2012","unstructured":"Kamath BM, Yin W, Miller H Outcomes of liver transplantation for patients with Alagille syndrome: the studies of pediatric liver transplantation experience. Liver Transpl. 18(8), 940\u2013948 (2012).","journal-title":"Liver Transpl."},{"issue":"7","key":"e_1_3_7_10_2","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/jgh.13738","article-title":"Diagnostic considerations for cholestatic liver disease","volume":"32","author":"Pollock G","year":"2017","unstructured":"Pollock G, Minuk GY. Diagnostic considerations for cholestatic liver disease. J. Gastroenterol. Hepatol. 32(7), 1303\u20131309 (2017).","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"2","key":"e_1_3_7_11_2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/hep.32761","article-title":"Natural history of liver disease in a large international cohort of children with Alagille syndrome: results from the GALA study","volume":"77","author":"Vandriel SM","year":"2023","unstructured":"Vandriel SM, Li LT, She H Natural history of liver disease in a large international cohort of children with Alagille syndrome: results from the GALA study. Hepatology 77(2), 512\u2013529 (2023).","journal-title":"Hepatology"},{"issue":"3","key":"e_1_3_7_12_2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1136\/gut.49.3.431","article-title":"Outcome of liver disease in children with Alagille syndrome: a study of 163 patients","volume":"49","author":"Lykavieris P","year":"2001","unstructured":"Lykavieris P, Hadchouel M, Chardot C, Bernard O. Outcome of liver disease in children with Alagille syndrome: a study of 163 patients. Gut 49(3), 431\u2013435 (2001).","journal-title":"Gut"},{"issue":"3","key":"e_1_3_7_13_2","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/hep.510290331","article-title":"Features of Alagille syndrome in 92 patients: frequency and relation to prognosis","volume":"29","author":"Emerick KM","year":"1999","unstructured":"Emerick KM, Rand EB, Goldmuntz E Features of Alagille syndrome in 92 patients: frequency and relation to prognosis. Hepatology 29(3), 822\u2013829 (1999).","journal-title":"Hepatology"},{"issue":"10311","key":"e_1_3_7_14_2","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(21)01256-3","article-title":"Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study","volume":"398","author":"Gonzales E","year":"2021","unstructured":"Gonzales E, Hardikar W, Stormon M Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. Lancet 398(10311), 1581\u20131592 (2021).","journal-title":"Lancet"},{"key":"e_1_3_7_15_2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jpeds.2022.09.001","article-title":"Maralixibat treatment response in Alagille syndrome is associated with improved health-related quality of life","volume":"252","author":"Kamath BM","year":"2023","unstructured":"Kamath BM, Goldstein A, Howard R Maralixibat treatment response in Alagille syndrome is associated with improved health-related quality of life. J. Pediatr. 252, 68\u201375 (2023).","journal-title":"J. Pediatr."},{"key":"e_1_3_7_16_2","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/JMDH.S295441","article-title":"Multidisciplinary management of Alagille syndrome","volume":"15","author":"Menon J","year":"2022","unstructured":"Menon J, Shanmugam N, Vij M, Rammohan A, Rela M. Multidisciplinary management of Alagille syndrome. J. Multidiscip. Healthc. 15, 353\u2013364 (2022).","journal-title":"J. Multidiscip. Healthc."},{"issue":"7","key":"e_1_3_7_17_2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/LVT.0000000000000082","article-title":"Costs of pediatric liver transplantation among commercially insured and Medicaid-insured patients with cholestasis in the US","volume":"29","author":"Miloh T","year":"2023","unstructured":"Miloh T, Goldstein A, Howard R Costs of pediatric liver transplantation among commercially insured and Medicaid-insured patients with cholestasis in the US. Liver Transpl. 29(7), 735\u2013744 (2023).","journal-title":"Liver Transpl."},{"key":"e_1_3_7_18_2","volume-title":"CRD's guidance for undertaking reviews in health care [Internet]","author":"Centre for Reviews and Dissemination","year":"2009","unstructured":"Centre for Reviews and Dissemination. CRD's guidance for undertaking reviews in health care [Internet]. CRD, University of York (2009) (Accessed: 13 August 2023). https:\/\/www.york.ac.uk\/media\/crd\/Systematic_Reviews.pdf"},{"issue":"12","key":"e_1_3_7_19_2","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1002\/humu.23879","article-title":"Alagille syndrome mutation update: comprehensive overview of JAG1 and NOTCH2 mutation frequencies and insight into missense variant classification","volume":"40","author":"Gilbert MA","year":"2019","unstructured":"Gilbert MA, Bauer RC, Rajagopalan R Alagille syndrome mutation update: comprehensive overview of JAG1 and NOTCH2 mutation frequencies and insight into missense variant classification. Hum. Mutat. 40(12), 2197\u20132220 (2019).","journal-title":"Hum. Mutat."},{"issue":"2","key":"e_1_3_7_20_2","first-page":"S57","article-title":"Unraveling the relationship between itching, scratch scales and biomarkers in children with Alagille syndrome","volume":"65","author":"Kamath B","year":"2017","unstructured":"Kamath B, Shneider B, Spino C Unraveling the relationship between itching, scratch scales and biomarkers in children with Alagille syndrome. J. Pediatr. Gastroenterol. Nutr. 65(Suppl. 2), S57\u2013S58 (2017).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"e_1_3_7_21_2","first-page":"S215","article-title":"Long-term renal dysfunction after pediatric living donor liver transplantation","volume":"18","author":"Lin YH","year":"2012","unstructured":"Lin YH, Lin CC, Wang CC Long-term renal dysfunction after pediatric living donor liver transplantation. Liver Transplant. 18, S215 (2012).","journal-title":"Liver Transplant."},{"key":"e_1_3_7_22_2","first-page":"882A","article-title":"Phenotypic divergence of JAGGED1 and NOTCH2-associated Alagille syndrome: results from the international multicenter GALA study group","volume":"72","author":"Vandriel S","year":"2020","unstructured":"Vandriel S, Li L, She H Phenotypic divergence of JAGGED1 and NOTCH2-associated Alagille syndrome: results from the international multicenter GALA study group. Hepatology 72, 882A\u2013884A (2020).","journal-title":"Hepatology"},{"issue":"10","key":"e_1_3_7_23_2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3345\/kjp.2015.58.10.392","article-title":"Alagille syndrome and a JAG1 mutation: 41 cases of experience at a single center","volume":"58","author":"Ahn KJ","year":"2015","unstructured":"Ahn KJ, Yoon JK, Kim GB Alagille syndrome and a JAG1 mutation: 41 cases of experience at a single center. Korean J. Pediatr. 58(10), 392\u2013397 (2015).","journal-title":"Korean J. Pediatr."},{"issue":"2","key":"e_1_3_7_24_2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.5301\/EJO.2010.5675","article-title":"Alagille syndrome: clinical and ocular pathognomonic features","volume":"21","author":"El-Koofy NM","year":"2011","unstructured":"El-Koofy NM, El-Mahdy R, Fahmy ME Alagille syndrome: clinical and ocular pathognomonic features. Eur. J. Ophthalmol. 21(2), 199\u2013206 (2011).","journal-title":"Eur. J. Ophthalmol."},{"key":"e_1_3_7_25_2","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.humpath.2020.12.007","article-title":"Dialogs in the assessment of neonatal cholestatic liver disease","volume":"112","author":"Cho SJ","year":"2021","unstructured":"Cho SJ, Perito ER, Shafizadeh N, Kim GE. Dialogs in the assessment of neonatal cholestatic liver disease. Hum. Pathol. 112, 102\u2013115 (2021).","journal-title":"Hum. Pathol."},{"issue":"4","key":"e_1_3_7_26_2","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00247-021-05200-x","article-title":"Congenital musculoskeletal anomalies - key radiographic findings","volume":"52","author":"Gill KG","year":"2022","unstructured":"Gill KG. Congenital musculoskeletal anomalies - key radiographic findings. Pediatr. Radiol. 52(4), 777\u2013785 (2022).","journal-title":"Pediatr. Radiol."},{"issue":"1","key":"e_1_3_7_27_2","first-page":"156","article-title":"Clinical and genetic characteristics of Alagille syndrome in adults","volume":"11","author":"Li J","year":"2023","unstructured":"Li J, Wu H, Chen S Clinical and genetic characteristics of Alagille syndrome in adults. J Clin Transl Hepatol. 11(1), 156\u2013162 (2023).","journal-title":"J Clin Transl Hepatol."},{"issue":"6","key":"e_1_3_7_28_2","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/MPG.0000000000001538","article-title":"Abdominal arterial anomalies in children with Alagille syndrome: surgical aspects and outcomes of liver transplantation","volume":"64","author":"Kohaut J","year":"2017","unstructured":"Kohaut J, Pommier R, Guerin F Abdominal arterial anomalies in children with Alagille syndrome: surgical aspects and outcomes of liver transplantation. J. Pediatr. Gastroenterol. Nutr. 64(6), 888\u2013891 (2017).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"1","key":"e_1_3_7_29_2","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1542\/peds.111.1.167","article-title":"Bleeding tendency in children with Alagille syndrome","volume":"111","author":"Lykavieris P","year":"2003","unstructured":"Lykavieris P, Crosnier C, Trichet C, Meunier-Rotival M, Hadchouel M. Bleeding tendency in children with Alagille syndrome. Pediatrics 111(1), 167\u2013170 (2003).","journal-title":"Pediatrics"},{"issue":"4","key":"e_1_3_7_30_2","first-page":"431","article-title":"Variable morbidity in Alagille syndrome: a review of 43 cases","volume":"29","author":"Quiros-Tejeira RE","year":"1999","unstructured":"Quiros-Tejeira RE, Ament ME, Heyman MB Variable morbidity in Alagille syndrome: a review of 43 cases. J. Pediatr. Gastroenterol. Nutr. 29(4), 431\u2013437 (1999).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"3","key":"e_1_3_7_31_2","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/hep4.1468","article-title":"Outcomes of childhood cholestasis in Alagille syndrome: results of a multicenter observational study","volume":"4","author":"Kamath BM","year":"2020","unstructured":"Kamath BM, Ye W, Goodrich NP Outcomes of childhood cholestasis in Alagille syndrome: results of a multicenter observational study. Hepatol. Commun. 4(3), 387\u2013398 (2020).","journal-title":"Hepatol. Commun."},{"issue":"1","key":"e_1_3_7_32_2","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/hep.30196","article-title":"Bone density in children with chronic liver disease correlates with growth and cholestasis","volume":"69","author":"Loomes KM","year":"2019","unstructured":"Loomes KM, Spino C, Goodrich NP Bone density in children with chronic liver disease correlates with growth and cholestasis. Hepatology 69(1), 245\u2013257 (2019).","journal-title":"Hepatology"},{"issue":"11","key":"e_1_3_7_33_2","article-title":"Alagille syndrome: diagnostic challenges and advances in management","volume":"10","author":"Ayoub MD","year":"2020","unstructured":"Ayoub MD, Kamath BM. Alagille syndrome: diagnostic challenges and advances in management. Diagnostics (Basel) 10(11), (2020).","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"e_1_3_7_34_2","first-page":"76","article-title":"Deficits in size-adjusted bone mass in children with Alagille syndrome","volume":"40","author":"Olsen IE","year":"2005","unstructured":"Olsen IE, Ittenbach RF, Rovner AJ Deficits in size-adjusted bone mass in children with Alagille syndrome. J. Pediatr. Gastroenterol. Nutr. 40(1), 76\u201382 (2005).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"1","key":"e_1_3_7_35_2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1525-1470.2005.22102.x","article-title":"Alagille syndrome: cutaneous manifestations in 38 children","volume":"22","author":"Garcia MA","year":"2005","unstructured":"Garcia MA, Ramonet M, Ciocca M Alagille syndrome: cutaneous manifestations in 38 children. Pediatr. Dermatol. 22(1), 11\u201314 (2005).","journal-title":"Pediatr. Dermatol."},{"issue":"8","key":"e_1_3_7_36_2","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1080\/02713683.2022.2081980","article-title":"Predictors of vision loss after surgery for macula-sparing rhegmatogenous retinal detachment","volume":"47","author":"Gopal A","year":"2022","unstructured":"Gopal A, Starr M, Obeid A Predictors of vision loss after surgery for macula-sparing rhegmatogenous retinal detachment. Curr. Eye Res. 47(8), 1209\u20131217 (2022).","journal-title":"Curr. Eye Res."},{"issue":"2","key":"e_1_3_7_37_2","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1080\/13816810.2021.2004432","article-title":"Macular atrophy in JAG1-related Alagille syndrome: a case series","volume":"43","author":"Paez-Escamilla M","year":"2022","unstructured":"Paez-Escamilla M, Scanga HL, Liasis A, Nischal KK. Macular atrophy in JAG1-related Alagille syndrome: a case series. Ophthalmic Genet. 43(2), 230\u2013234 (2022).","journal-title":"Ophthalmic Genet."},{"issue":"1","key":"e_1_3_7_38_2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/MPG.0000000000003337","article-title":"Neurodevelopmental outcomes in children with inherited liver disease and native liver","volume":"74","author":"Leung DH","year":"2022","unstructured":"Leung DH, Sorensen LG, Ye W Neurodevelopmental outcomes in children with inherited liver disease and native liver. J. Pediatr. Gastroenterol. Nutr. 74(1), 96\u2013103 (2022).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"2","key":"e_1_3_7_39_2","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1399-3046.2005.00432.x","article-title":"Liver transplantation in children with Alagille syndrome: indications and outcome","volume":"10","author":"Englert C","year":"2006","unstructured":"Englert C, Grabhorn E, Burdelski M, Ganschow R. Liver transplantation in children with Alagille syndrome: indications and outcome. Pediatr. Transplant. 10(2), 154\u2013158 (2006).","journal-title":"Pediatr. Transplant."},{"key":"e_1_3_7_40_2","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jpeds.2019.10.042","article-title":"Alagille syndrome and chronic arthritis: an international case series","volume":"218","author":"Ferrara G","year":"2020","unstructured":"Ferrara G, Giani T, Lieberman SM Alagille syndrome and chronic arthritis: an international case series. J. Pediatr. 218, 228\u2013230.e1 (2020).","journal-title":"J. Pediatr."},{"issue":"1","key":"e_1_3_7_41_2","doi-asserted-by":"crossref","DOI":"10.1093\/ejcts\/ezac553","article-title":"Impact of liver dysfunction on outcomes in children with Alagille syndrome undergoing congenital heart surgery","volume":"63","author":"Mainwaring RD","year":"2022","unstructured":"Mainwaring RD, Felmly LM, Collins RT, Hanley FL. Impact of liver dysfunction on outcomes in children with Alagille syndrome undergoing congenital heart surgery. Eur. J. Cardiothorac. Surg. 63(1), (2022).","journal-title":"Eur. J. Cardiothorac. Surg."},{"issue":"12","key":"e_1_3_7_42_2","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1097\/01.TP.0000066804.33006.17","article-title":"Living-related liver transplantation for Alagille syndrome","volume":"75","author":"Kasahara M","year":"2003","unstructured":"Kasahara M, Kiuchi T, Inomata Y Living-related liver transplantation for Alagille syndrome. Transplantation 75(12), 2147\u20132150 (2003).","journal-title":"Transplantation"},{"key":"e_1_3_7_43_2","doi-asserted-by":"crossref","first-page":"S554","DOI":"10.1016\/S0168-8278(20)31582-8","article-title":"Clinical features and natural history of 1154 Alagille syndrome patients: results from the international multicenter GALA study group","volume":"73","author":"Vandriel S","year":"2020","unstructured":"Vandriel S, Liting L, She H Clinical features and natural history of 1154 Alagille syndrome patients: results from the international multicenter GALA study group. J. Hepatol. 73, S554\u2013S555 (2020).","journal-title":"J. Hepatol."},{"key":"e_1_3_7_44_2","first-page":"55A","article-title":"Clinical features and outcomes in an international cohort of 731 Alagille syndrome patients from 19 countries","volume":"70","author":"Vandriel S","year":"2019","unstructured":"Vandriel S, Wang JS, Li L Clinical features and outcomes in an international cohort of 731 Alagille syndrome patients from 19 countries. Hepatology 70, 55A\u201356A (2019).","journal-title":"Hepatology"},{"issue":"8","key":"e_1_3_7_45_2","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1111\/liv.14553","article-title":"Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis","volume":"40","author":"Kamath BM","year":"2020","unstructured":"Kamath BM, Stein P, Houwen RHJ, Verkade HJ. Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis. Liver Int. 40(8), 1812\u20131822 (2020).","journal-title":"Liver Int."},{"issue":"3","key":"e_1_3_7_46_2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hep4.1305","article-title":"A randomized, controlled, phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis","volume":"3","author":"Mayo MJ","year":"2019","unstructured":"Mayo MJ, Pockros PJ, Jones D A randomized, controlled, phase 2 study of maralixibat in the treatment of itching associated with primary biliary cholangitis. Hepatol Commun. 3(3), 365\u2013381 (2019).","journal-title":"Hepatol Commun."},{"issue":"2","key":"e_1_3_7_47_2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/MPG.0b013e318297e384","article-title":"Management of cholestatic pruritus in paediatric patients with Alagille syndrome: the King's College Hospital experience","volume":"57","author":"Kronsten V","year":"2013","unstructured":"Kronsten V, Fitzpatrick E, Baker A. Management of cholestatic pruritus in paediatric patients with Alagille syndrome: the King's College Hospital experience. J. Pediatr. Gastroenterol. Nutr. 57(2), 149\u2013154 (2013).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"6","key":"e_1_3_7_48_2","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/MPG.0b013e3181ef3771","article-title":"Health status of patients with Alagille syndrome","volume":"51","author":"Elisofon SA","year":"2010","unstructured":"Elisofon SA, Emerick KM, Sinacore JM, Alonso EM. Health status of patients with Alagille syndrome. J. Pediatr. Gastroenterol. Nutr. 51(6), 759\u2013765 (2010).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"1","key":"e_1_3_7_49_2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40271-017-0266-4","article-title":"Development of a novel tool to assess the impact of itching in pediatric cholestasis","volume":"11","author":"Kamath BM","year":"2018","unstructured":"Kamath BM, Abetz-Webb L, Kennedy C Development of a novel tool to assess the impact of itching in pediatric cholestasis. Patient 11(1), 69\u201382 (2018).","journal-title":"Patient"},{"key":"e_1_3_7_50_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1471-230X-8-47","article-title":"Bile composition in Alagille syndrome and PFIC patients having partial external biliary diversion","volume":"8","author":"Emerick KM","year":"2008","unstructured":"Emerick KM, Elias MS, Melin-Aldana H Bile composition in Alagille syndrome and PFIC patients having partial external biliary diversion. BMC Gastroenterol. 8, 47 (2008).","journal-title":"BMC Gastroenterol."},{"issue":"3","key":"e_1_3_7_51_2","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jhep.2016.04.032","article-title":"Biliary atresia and other cholestatic childhood diseases: advances and future challenges","volume":"65","author":"Verkade HJ","year":"2016","unstructured":"Verkade HJ, Bezerra JA, Davenport M Biliary atresia and other cholestatic childhood diseases: advances and future challenges. J. Hepatol. 65(3), 631\u2013642 (2016).","journal-title":"J. Hepatol."},{"issue":"6","key":"e_1_3_7_52_2","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1053\/jhep.2002.33332","article-title":"Partial external biliary diversion for intractable pruritus and xanthomas in Alagille syndrome","volume":"35","author":"Emerick KM","year":"2002","unstructured":"Emerick KM, Whitington PF. Partial external biliary diversion for intractable pruritus and xanthomas in Alagille syndrome. Hepatology 35(6), 1501\u20131506 (2002).","journal-title":"Hepatology"},{"issue":"10","key":"e_1_3_7_53_2","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/hep4.1244","article-title":"Placebo-controlled randomized trial of an intestinal bile salt transport inhibitor for pruritus in Alagille syndrome","volume":"2","author":"Shneider BL","year":"2018","unstructured":"Shneider BL, Spino C, Kamath BM Placebo-controlled randomized trial of an intestinal bile salt transport inhibitor for pruritus in Alagille syndrome. Hepatol Commun. 2(10), 1184\u20131198 (2018).","journal-title":"Hepatol Commun."},{"issue":"5","key":"e_1_3_7_54_2","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/hep.29019","article-title":"Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis","volume":"65","author":"Wang KS","year":"2017","unstructured":"Wang KS, Tiao G, Bass LM Analysis of surgical interruption of the enterohepatic circulation as a treatment for pediatric cholestasis. Hepatology 65(5), 1645\u20131654 (2017).","journal-title":"Hepatology"},{"issue":"8","key":"e_1_3_7_55_2","doi-asserted-by":"crossref","first-page":"e13579","DOI":"10.1111\/petr.13579","article-title":"Living donor liver transplantation in Alagille syndrome-single center experience from south Asia","volume":"23","author":"Valamparampil JJ","year":"2019","unstructured":"Valamparampil JJ, Reddy MS, Shanmugam N Living donor liver transplantation in Alagille syndrome-single center experience from south Asia. Pediatr. Transplant. 23(8), e13579 (2019).","journal-title":"Pediatr. Transplant."},{"issue":"3","key":"e_1_3_7_56_2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/MPG.0000000000003522","article-title":"Pediatric liver transplant survival in Alagille syndrome is comparable to biliary atresia - a linked database analysis","volume":"75","author":"Black K","year":"2022","unstructured":"Black K, Ziogas IA, Thurm C Pediatric liver transplant survival in Alagille syndrome is comparable to biliary atresia - a linked database analysis. J. Pediatr. Gastroenterol. Nutr. 75(3), 257\u2013263 (2022).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"2","key":"e_1_3_7_57_2","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/hep.32760","article-title":"The Global Alagille Alliance study: redefining the natural history of Alagille syndrome","volume":"77","author":"Habash N","year":"2023","unstructured":"Habash N, Ibrahim SH. The Global Alagille Alliance study: redefining the natural history of Alagille syndrome. Hepatology 77(2), 347\u2013349 (2023).","journal-title":"Hepatology"},{"key":"e_1_3_7_58_2","first-page":"73","article-title":"Liver transplantation in Alagille syndrome patients","volume":"17","author":"Gliwicz-Miedzinska D","year":"2013","unstructured":"Gliwicz-Miedzinska D, Czubkowski P, Jankowska I, Kalicinski P, Pawlowska J. Liver transplantation in Alagille syndrome patients. Pediatr. Transplant. 17, 73\u201373 (2013).","journal-title":"Pediatr. Transplant."},{"key":"e_1_3_7_59_2","unstructured":"OPTN\/SRTR 2022 annual data report [Internet]. HRSA. (Accessed: 29 April 2024). https:\/\/srtr.transplant.hrsa.gov\/annual_reports\/2022_ADR_Preview.aspx"},{"key":"e_1_3_7_60_2","doi-asserted-by":"crossref","first-page":"e936801","DOI":"10.12659\/MSM.936801","article-title":"Physical and psychosocial concept domains related to health-related quality of life (HRQL) in 50 girls and 52 boys between 5 and 18 years old in Poland using the Parent-Reported 50-Item Child Health Questionnaire (CHQ-PF50)","volume":"28","author":"Chmielik LP","year":"2022","unstructured":"Chmielik LP, Mielnik-Niedzielska G, Kasprzyk A, Stankiewicz T, Niedzielski A. Physical and psychosocial concept domains related to health-related quality of life (HRQL) in 50 girls and 52 boys between 5 and 18 years old in Poland using the Parent-Reported 50-Item Child Health Questionnaire (CHQ-PF50). Med. Sci. Monit. 28, e936801 (2022).","journal-title":"Med. Sci. Monit."},{"issue":"23","key":"e_1_3_7_61_2","first-page":"S45","article-title":"The Czech version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ)","volume":"19","author":"Dolezalova P","year":"2001","unstructured":"Dolezalova P, Ruperto N, Nemcova D The Czech version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin. Exp. Rheumatol. 19(23 Suppl. 4), S45\u2013S49 (2001).","journal-title":"Clin. Exp. Rheumatol."},{"issue":"23","key":"e_1_3_7_62_2","first-page":"S1","article-title":"Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology","volume":"19","author":"Ruperto N","year":"2001","unstructured":"Ruperto N, Ravelli A, Pistorio A Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries. Review of the general methodology. Clin. Exp. Rheumatol. 19(23 Suppl. 4), S1\u2013S9 (2001).","journal-title":"Clin. Exp. Rheumatol."},{"issue":"2","key":"e_1_3_7_63_2","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jpeds.2015.04.077","article-title":"Quality of life and its determinants in a multicenter cohort of children with Alagille syndrome","volume":"167","author":"Kamath BM","year":"2015","unstructured":"Kamath BM, Chen Z, Romero R Quality of life and its determinants in a multicenter cohort of children with Alagille syndrome. J. Pediatr. 167(2), 390\u2013396.e393 (2015).","journal-title":"J. Pediatr."},{"issue":"6","key":"e_1_3_7_64_2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1367\/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2","article-title":"The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity","volume":"3","author":"Varni JW","year":"2003","unstructured":"Varni JW, Burwinkle TM, Seid M, Skarr D. The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. Ambul. Pediatr. 3(6), 329\u2013341 (2003).","journal-title":"Ambul. Pediatr."},{"key":"e_1_3_7_65_2","volume-title":"Presented at the The Professional Society for Health Economics and Outcomes Research (ISPOR) Europe","author":"Quadrado L","year":"2022","unstructured":"Quadrado L, Mogul D, Gurevich A Patient and caregiver burden associated with caring for a child with Alagille syndrome: mixed-methods development of health state vignettes. Presented at the The Professional Society for Health Economics and Outcomes Research (ISPOR) Europe. Vienna, Austria; and Virtual (November 6\u20139, 2022)."},{"issue":"1","key":"e_1_3_7_66_2","first-page":"S403","article-title":"Caregiver burden associated with caring for a child with Alagille syndrome: a multi-national, quantitative analysis","volume":"75","author":"Quadrado L","year":"2022","unstructured":"Quadrado L, Mogul D, Gurevich A Caregiver burden associated with caring for a child with Alagille syndrome: a multi-national, quantitative analysis. Pediatr Gastroenterol Hepatol Nutr. 75(1), S403\u2013S404 (2022).","journal-title":"Pediatr Gastroenterol Hepatol Nutr."},{"issue":"1","key":"e_1_3_7_67_2","doi-asserted-by":"crossref","first-page":"e13642","DOI":"10.1111\/petr.13642","article-title":"The impact of caregiver post-traumatic stress and depressive symptoms on pediatric transplant outcomes","volume":"24","author":"Annunziato RA","year":"2020","unstructured":"Annunziato RA, Stuber ML, Supelana CJ The impact of caregiver post-traumatic stress and depressive symptoms on pediatric transplant outcomes. Pediatr. Transplant. 24(1), e13642 (2020).","journal-title":"Pediatr. Transplant."},{"key":"e_1_3_7_68_2","unstructured":"ClinicalTrials.gov. NCT02160782. (Accessed: 9 December 2024). https:\/\/clinicaltrials.gov\/study\/NCT02160782"},{"key":"e_1_3_7_69_2","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S0618-8278(19)30211-7","article-title":"Phase 2 open-label study with a placebo-controlled drug withdrawal period of the apical sodium-dependent bile acid transporter inhibitor maralixibat in children with Alagille syndrome: 48-week interim efficacy analysis","volume":"70","author":"Gonzales EMS E","year":"2019","unstructured":"Gonzales EMS E, Stormon M, Sokal E Phase 2 open-label study with a placebo-controlled drug withdrawal period of the apical sodium-dependent bile acid transporter inhibitor maralixibat in children with Alagille syndrome: 48-week interim efficacy analysis. J. Hepatol. 70, e119\u2013e120 (2019).","journal-title":"J. Hepatol."},{"key":"e_1_3_7_70_2","doi-asserted-by":"crossref","unstructured":"Gonzales E Hardikar W Stormon M Maralixibat treatment significantly reduces pruritus and serum bile acids in patients with Alagille syndrome: results from a randomized phase II study with 4 years of follow-up. https:\/\/ssrn.com\/abstract=3756810 (Accessed: 13 August 2023) (2021).","DOI":"10.2139\/ssrn.3756810"},{"key":"e_1_3_7_71_2","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jpeds.2022.09.033","article-title":"Health care resource utilization by patients with Alagille syndrome","volume":"253","author":"Ebel NH","year":"2023","unstructured":"Ebel NH, Goldstein A, Howard R Health care resource utilization by patients with Alagille syndrome. J. Pediatr. 253, 144\u2013151 (2023).","journal-title":"J. Pediatr."},{"key":"e_1_3_7_72_2","doi-asserted-by":"crossref","first-page":"295891","DOI":"10.1155\/2015\/295891","article-title":"Management of pruritus in chronic liver disease","volume":"2015","author":"Bhalerao A","year":"2015","unstructured":"Bhalerao A, Mannu GS. Management of pruritus in chronic liver disease. Dermatol. Res. Pract. 2015, 295891 (2015).","journal-title":"Dermatol. Res. Pract."},{"issue":"5","key":"e_1_3_7_73_2","article-title":"Cholestatic pruritus in children: conventional therapies and beyond","volume":"12","author":"Rodrigo M","year":"2023","unstructured":"Rodrigo M, Dong X, Chien D, Karnsakul W. Cholestatic pruritus in children: conventional therapies and beyond. Biology (Basel) 12(5), (2023).","journal-title":"Biology (Basel)"},{"issue":"6","key":"e_1_3_7_74_2","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/MPG.0b013e3181d98ea8","article-title":"Medical management of Alagille syndrome","volume":"50","author":"Kamath BM","year":"2010","unstructured":"Kamath BM, Loomes KM, Piccoli DA. Medical management of Alagille syndrome. J. Pediatr. Gastroenterol. Nutr. 50(6), 580\u2013586 (2010).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"12","key":"e_1_3_7_75_2","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1194\/jlr.R900012-JLR200","article-title":"Bile acid transporters","volume":"50","author":"Dawson PA","year":"2009","unstructured":"Dawson PA, Lan T, Rao A. Bile acid transporters. J. Lipid Res. 50(12), 2340\u20132357 (2009).","journal-title":"J. Lipid Res."},{"issue":"5","key":"e_1_3_7_76_2","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.clinre.2017.02.001","article-title":"An important intestinal transporter that regulates the enterohepatic circulation of bile acids and cholesterol homeostasis: the apical sodium-dependent bile acid transporter (SLC10A2\/ASBT)","volume":"41","author":"Xiao L","year":"2017","unstructured":"Xiao L, Pan G. An important intestinal transporter that regulates the enterohepatic circulation of bile acids and cholesterol homeostasis: the apical sodium-dependent bile acid transporter (SLC10A2\/ASBT). Clin. Res. Hepatol. Gastroenterol. 41(5), 509\u2013515 (2017).","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"e_1_3_7_77_2","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3389\/fphar.2018.00931","article-title":"Ileal bile acid transporter inhibition for the treatment of chronic constipation, cholestatic pruritus, and NASH","volume":"9","author":"Al-Dury S","year":"2018","unstructured":"Al-Dury S, Marschall HU. Ileal bile acid transporter inhibition for the treatment of chronic constipation, cholestatic pruritus, and NASH. Front. Pharmacol. 9, 931 (2018).","journal-title":"Front. Pharmacol."},{"issue":"2","key":"e_1_3_7_78_2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/hep.27973","article-title":"Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice","volume":"63","author":"Miethke AG","year":"2016","unstructured":"Miethke AG, Zhang W, Simmons J Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice. Hepatology 63(2), 512\u2013523 (2016).","journal-title":"Hepatology"},{"issue":"1","key":"e_1_3_7_79_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12876-017-0736-0","article-title":"Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial","volume":"18","author":"Tiessen RG","year":"2018","unstructured":"Tiessen RG, Kennedy CA, Keller BT Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial. BMC Gastroenterol. 18(1), 3 (2018).","journal-title":"BMC Gastroenterol."},{"key":"e_1_3_7_80_2","unstructured":"European Medicines Agency (EMA). Livmarli oral solution. Summary of product characteristics. (2024) (Accessed: 25 July 25 2024). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/livmarli-epar-product-information_en.pdf"},{"key":"e_1_3_7_81_2","unstructured":"Food and Drug Administration (FDA). Livmarli (maralixibat) oral solution. Prescribing information. (2024) (Accessed: 15 August 2024). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214662s000lbl.pdf"},{"issue":"1","key":"e_1_3_7_82_2","first-page":"223A","article-title":"Pruritus intensity is associated with cholestasis biomarkers and quality of life measures after maralixibat treatment in children with Alagille syndrome","volume":"72","author":"Gonzales EM","year":"2020","unstructured":"Gonzales EM, Vig P, Tucker E Pruritus intensity is associated with cholestasis biomarkers and quality of life measures after maralixibat treatment in children with Alagille syndrome. Hepatology 72(Suppl. 1), 223A (2020).","journal-title":"Hepatology"},{"issue":"8","key":"e_1_3_7_83_2","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1002\/hep4.1992","article-title":"Impact of long-term administration of maralixibat on children with cholestasis secondary to Alagille syndrome","volume":"6","author":"Shneider BL","year":"2022","unstructured":"Shneider BL, Spino CA, Kamath BM Impact of long-term administration of maralixibat on children with cholestasis secondary to Alagille syndrome. Hepatol. Commun. 6(8), 1922\u20131933 (2022).","journal-title":"Hepatol. Commun."},{"key":"e_1_3_7_84_2","volume-title":"Presented at the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting","author":"Kamath BM","year":"2022","unstructured":"Kamath BM, Mogul DB, Baek M, Nunes T, Vig P. Maralixabat improves growth in patients with alagile syndrome: a 4-year analysis. Presented at the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Annual Meeting. Copenhagen, Denmark (June 22\u201325, 2022)."},{"issue":"6","key":"e_1_3_7_85_2","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1097\/HEP.0000000000000727","article-title":"Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA","volume":"79","author":"Hansen BE","year":"2023","unstructured":"Hansen BE, Vandriel SM, Vig P Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA. Hepatology 79(6), 1279\u20131292 (2023).","journal-title":"Hepatology"},{"issue":"1","key":"e_1_3_7_86_2","first-page":"S262","article-title":"Safety and tolerability of maralixibat in infants from 2 months of age with Alagille syndrome or progressive familial intrahepatic cholestasis: results from the RISE study","volume":"77","author":"Rosenthal P","year":"2023","unstructured":"Rosenthal P, Thompson R, Jankowska I Safety and tolerability of maralixibat in infants from 2 months of age with Alagille syndrome or progressive familial intrahepatic cholestasis: results from the RISE study. J. Pediatr. Gastroenterol. Nutr. 77(1 Suppl. 1), S262\u2013S263 (2023).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"e_1_3_7_87_2","unstructured":"Food and Drug Administration (FDA). Bylvay (odevixibat). Prescribing information. (2021) (Accessed: 29 April 2024) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215498s000lbl.pdf"},{"key":"e_1_3_7_88_2","unstructured":"European Medicines Agency (EMA). Bylvay (odevixibat). Summary of product characteristics. (2024) (Accessed: 29 April 2024). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bylvay-epar-product-information_en.pdf"},{"key":"e_1_3_7_89_2","volume-title":"Presented at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting","author":"Ovchinsky N","year":"2022","unstructured":"Ovchinsky N, Aumar M, Alastair Baker A Efficacy and safety of odevixibat in patients with Alagille syndrome: top-line results from ASSERT, a phase III, double-blind, randomized, placebo-controlled study. Presented at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting. Washington, DC, USA (November 4\u20138, 2022)."},{"issue":"7","key":"e_1_3_7_90_2","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S2468-1253(24)00074-8","article-title":"Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase III, double-blind, randomised, placebo-controlled trial","volume":"9","author":"Ovchinsky N","year":"2024","unstructured":"Ovchinsky N, Aumar M, Baker A Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase III, double-blind, randomised, placebo-controlled trial. The Lancet Gastroenterology & Hepatology 9(7), 632\u2013645 (2024).","journal-title":"The Lancet Gastroenterology & Hepatology"},{"issue":"1","key":"e_1_3_7_91_2","first-page":"S191","article-title":"The ASSERT study: a phase III double-blind, randomized, placebo-controlled study of the safety and efficacy of odevixibat in patients with Alagille syndrome","volume":"73","author":"Ovchinsky N","year":"2021","unstructured":"Ovchinsky N, Savage J, Kjems L, Horn P. The ASSERT study: a phase III double-blind, randomized, placebo-controlled study of the safety and efficacy of odevixibat in patients with Alagille syndrome. J. Pediatr. Gastroenterol. Nutr. 73(1 Suppl. 1), S191\u2013S192 (2021).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"1","key":"e_1_3_7_92_2","first-page":"701","article-title":"Efficacy and safety of odevixibat in patients with Alagille syndrome: interim results from the open-label, phase III ASSERT-EXT study","volume":"76","author":"Ovchinsky N","year":"2023","unstructured":"Ovchinsky N, Aumar M, Baker A Efficacy and safety of odevixibat in patients with Alagille syndrome: interim results from the open-label, phase III ASSERT-EXT study. J. Pediatr. Gastroenterol. Nutr. 76(Suppl. 1), 701\u2013703 (2023).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"e_1_3_7_93_2","doi-asserted-by":"crossref","first-page":"S166","DOI":"10.1016\/j.jval.2020.04.470","article-title":"PIH76 Itch reported outcome tool for caregivers of pediatric patients with cholestatic liver disease: an analysis of validation and scoring from the ICONIC maralixibat study","volume":"23","author":"Foster B","year":"2020","unstructured":"Foster B, Gauthier M, Vig P PIH76 Itch reported outcome tool for caregivers of pediatric patients with cholestatic liver disease: an analysis of validation and scoring from the ICONIC maralixibat study. Value Health 23, S166 (2020).","journal-title":"Value Health"},{"key":"e_1_3_7_94_2","first-page":"1479A","article-title":"Durability of treatment effect with long-term maralixibat in children with Alagille syndrome: 4-year safety and efficacy results from the ICONIC study","volume":"70","author":"Gonzales EM","year":"2019","unstructured":"Gonzales EM, Sturm E, Stormon M Durability of treatment effect with long-term maralixibat in children with Alagille syndrome: 4-year safety and efficacy results from the ICONIC study. Hepatology 70, 1479A (2019).","journal-title":"Hepatology"},{"issue":"1","key":"e_1_3_7_95_2","first-page":"S207","article-title":"Response to treatment with maralixibat in Alagille syndrome is associated with improved health-related quality of life","volume":"73","author":"Kamath B","year":"2021","unstructured":"Kamath B, Goldstein A, Howard R Response to treatment with maralixibat in Alagille syndrome is associated with improved health-related quality of life. J. Pediatr. Gastroenterol. Nutr. 73(Suppl. 1), S207\u2013S208 (2021).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"e_1_3_7_96_2","unstructured":"ClinicalTrials.gov. NCT01903460. (Accessed: 9 December 9 2024). https:\/\/clinicaltrials.gov\/study\/NCT01903460?cond=NCT01903460&rank=1"},{"key":"e_1_3_7_97_2","unstructured":"ClinicalTrials.gov. NCT04168385. (Accessed: 9 December 9 2024). https:\/\/clinicaltrials.gov\/study\/NCT04168385?cond=NCT04168385%20&rank=1"},{"key":"e_1_3_7_98_2","unstructured":"The GLobal ALagille Alliance Study (GALA). Participating Centres. (Accessed: 13 August 2023). https:\/\/www.galastudy.com\/participating-centres"},{"key":"e_1_3_7_99_2","volume-title":"Presented at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual Meeting (NASPGHAN)","author":"Murray K","year":"2024","unstructured":"Murray K, Kamath B, Gonzales E Clinical benefits of maralixibat for patients with Alagille syndrome are durable through 7 years of treatment: data from the MERGE study. Presented at the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition Annual Meeting (NASPGHAN). Hollywood, Florida, USA (November 6\u20139, 2024)."},{"key":"e_1_3_7_100_2","unstructured":"ClinicalTrials.gov. NCT04729751. (Accessed: 9 December 9 2024). https:\/\/clinicaltrials.gov\/study\/NCT04729751?cond=NCT04729751&rank=1"},{"issue":"1","key":"e_1_3_7_101_2","first-page":"777","article-title":"Safety and tolerability of maralixibat in infants from 2 months of age with Alagille syndrome or progressive familial intrahepatic cholestasis: results from the RISE study","volume":"76","author":"Gonzales E","year":"2023","unstructured":"Gonzales E, Jankowska I, Horslen S Safety and tolerability of maralixibat in infants from 2 months of age with Alagille syndrome or progressive familial intrahepatic cholestasis: results from the RISE study. J. Pediatr. Gastroenterol. Nutr. 76(Suppl. 1), 777 (2023).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"e_1_3_7_102_2","first-page":"S2106","article-title":"Outcomes with odevixibat treatment in patients with Alagille syndrome: analysis of pruritus responders from the phase III ASSERT study","volume":"78","author":"Ovchinsky N","year":"2023","unstructured":"Ovchinsky N, Aumar M, Baker AJ Outcomes with odevixibat treatment in patients with Alagille syndrome: analysis of pruritus responders from the phase III ASSERT study. Hepatology 78, S2106\u2013S2107 (2023).","journal-title":"Hepatology"},{"issue":"1","key":"e_1_3_7_103_2","first-page":"S256","article-title":"Changes in hepatic parameters in patients with Alagille syndrome treated with odevixibat: pooled data from the phase III ASSERT and ASSERT-EXT studies","volume":"77","author":"Ovchinsky N","year":"2023","unstructured":"Ovchinsky N, Aumar MB, Baker A Changes in hepatic parameters in patients with Alagille syndrome treated with odevixibat: pooled data from the phase III ASSERT and ASSERT-EXT studies. J. Pediatr. Gastroenterol. Nutr. 77(1 Suppl. 1), S256\u2013S257 (2023).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"5","key":"e_1_3_7_104_2","first-page":"E135","article-title":"Safety and tolerability characterization of maralixibat in infants with ALGS from 2 months of age: interim results from the RISE study","volume":"77","author":"Gonzales E","year":"2023","unstructured":"Gonzales E, Jankowska I, Horslen SP Safety and tolerability characterization of maralixibat in infants with ALGS from 2 months of age: interim results from the RISE study. Hepatology 77(5), E135 (2023).","journal-title":"Hepatology"},{"issue":"1","key":"e_1_3_7_105_2","first-page":"698","article-title":"Efficacy and safety of odevixibat in patients with Alagille syndrome: top-line results from ASSERT, a phase III, double-blind, randomized, placebo-controlled study","volume":"76","author":"Ovchinsky N","year":"2023","unstructured":"Ovchinsky N, Aumar M, Baker A Efficacy and safety of odevixibat in patients with Alagille syndrome: top-line results from ASSERT, a phase III, double-blind, randomized, placebo-controlled study. J. Pediatr. Gastroenterol. Nutr. 76(Suppl. 1), 698\u2013700 (2023).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"8","key":"e_1_3_7_106_2","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1016\/j.ajhg.2024.06.011","article-title":"Functional characterization of 2,832 JAG1 variants supports reclassification for Alagille syndrome and improves guidance for clinical variant interpretation","volume":"111","author":"Gilbert MA","year":"2024","unstructured":"Gilbert MA, Keefer-Jacques E, Jadhav T Functional characterization of 2,832 JAG1 variants supports reclassification for Alagille syndrome and improves guidance for clinical variant interpretation. Am. J. Hum. Genet. 111(8), 1656\u20131672 (2024).","journal-title":"Am. J. Hum. Genet."},{"key":"e_1_3_7_107_2","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.3389\/fpsyg.2019.01780","article-title":"The caregiving experiences of fathers and mothers of children with rare diseases in Italy: challenges and social support perceptions","volume":"10","author":"Cardinali P","year":"2019","unstructured":"Cardinali P, Migliorini L, Rania N. The caregiving experiences of fathers and mothers of children with rare diseases in Italy: challenges and social support perceptions. Front Psychol. 10, 1780 (2019).","journal-title":"Front Psychol."},{"key":"e_1_3_7_108_2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2431-13-153","article-title":"The impact of severe osteogenesis imperfecta on the lives of young patients and their parents - a qualitative analysis","volume":"13","author":"Dogba MJ","year":"2013","unstructured":"Dogba MJ, Bedos C, Durigova M The impact of severe osteogenesis imperfecta on the lives of young patients and their parents - a qualitative analysis. BMC Pediatr. 13, 153 (2013).","journal-title":"BMC Pediatr."},{"issue":"10","key":"e_1_3_7_109_2","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/lt.22130","article-title":"Patients on the waiting list for liver transplantation: caregiver burden and stress","volume":"16","author":"Miyazaki ET","year":"2010","unstructured":"Miyazaki ET, Dos Santos R Jr, Miyazaki MC Patients on the waiting list for liver transplantation: caregiver burden and stress. Liver Transpl. 16(10), 1164\u20131168 (2010).","journal-title":"Liver Transpl."},{"key":"e_1_3_7_110_2","first-page":"E83","article-title":"Management of pruritus in paediatric patients with Alagille syndrome: a review of 15 years' experience","volume":"52","author":"Kronsten VT","year":"2011","unstructured":"Kronsten VT, Fitzpatrick E, Baker A. Management of pruritus in paediatric patients with Alagille syndrome: a review of 15 years' experience. J. Pediatr. Gastroenterol. Nutr. 52, E83 (2011).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"3","key":"e_1_3_7_111_2","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/MPG.0000000000001385","article-title":"Sertraline as an additional treatment for cholestatic pruritus in children","volume":"64","author":"Thebaut A","year":"2017","unstructured":"Thebaut A, Habes D, Gottrand F Sertraline as an additional treatment for cholestatic pruritus in children. J. Pediatr. Gastroenterol. Nutr. 64(3), 431\u2013435 (2017).","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"11","key":"e_1_3_7_112_2","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/lt.25863","article-title":"Outcomes of liver transplantation among older recipients with nonalcoholic steatohepatitis in a large multicenter US cohort: the re-evaluating age limits in transplantation consortium","volume":"26","author":"Kwong AJ","year":"2020","unstructured":"Kwong AJ, Devuni D, Wang C Outcomes of liver transplantation among older recipients with nonalcoholic steatohepatitis in a large multicenter US cohort: the re-evaluating age limits in transplantation consortium. Liver Transpl. 26(11), 1492\u20131503 (2020).","journal-title":"Liver Transpl."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2024-0188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T12:08:59Z","timestamp":1738066139000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2024-0188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":111,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["10.57264\/cer-2024-0188"],"URL":"https:\/\/doi.org\/10.57264\/cer-2024-0188","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]},"article-number":"e240188"}}